Nanologica's Rights Issue Registered - Conversion of BTA to Shares

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Nanologica AB's (publ) rights issue of shares that ended on 13 March 2024 has been registered with the Swedish Companies Registration Office. The rights issue was subscribed to 100 percent leading to the company receiving MSEK 54,2 before issue costs and offsetting of loans.

The rights issue has been registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") is 8 April 2024. The record date is 10 April 2024, after which the BTA is converted into shares. The newly issued shares are expected to be available in each shareholder's custody/securities account on 12 April 2024.

Through the rights issues, the number of shares in Nanologica increases by 8,032,476 shares from 36,146,142 shares to 44,178,618 shares, and the share capital increases by approximately SEK 3,293,538.36, from SEK 14,820,922.61 to SEK 18,114,460.97. The Extraordinary General Meeting on 22 February 2024 resolved to reduce the share capital by an amount in SEK corresponding to the amount by which the share capital increases through the rights issue. The effect of this decision is that the company's share capital does not increase in connection with the registration of the rights issue.

ISIN code for share in Nanologica, ticker NICA: SE0005454873
ISIN code for BTA in Nanologica, ticker NICA BTA: SE0021626900

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
[email protected]
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.